Psychedelic Science Newsletter
Issue #33April 20, 20267 studies

Psilocybin's hallucinations and brain rewiring happen through completely different mechanisms

This week brought major insights into how psychedelics work in the brain, from separating hallucinations from healing effects to understanding why clinical trials struggle with the placebo problem.

🧠 Scientists separate psilocybin's trip from its therapeutic effects

  • Researchers used advanced brain imaging to show that psilocybin promotes new synapse formation while accelerating elimination of old synapses

  • Manipulating serotonin 2A receptors in specific brain cells (layer 5 pyramidal neurons) revealed these receptors are necessary for brain rewiring but not for hallucinations

  • The findings suggest psilocybin's therapeutic benefits could potentially be separated from its psychoactive effects

Why it matters: This could lead to treatments that provide psilocybin's antidepressant benefits without the intense psychological experience that limits clinical use.

Key Findings

🎭 Most psychedelic trials fail the blindness test

  • Analysis of 112 randomized trials found only 29.5% actually tested whether participants could guess their treatment

  • When tested, functional unblinding was massive: over 90% of participants correctly identified they received psilocybin, LSD, or ayahuasca instead of placebo

  • MDMA trials with inactive placebos exceeded 85% correct guesses, while ketamine studies rarely assessed blinding at all (17.9%)

💡 The placebo problem may be inflating psychedelic treatment effects in clinical trials.
🥇 Top 1% journal 🔗 JAMA psychiatry Journal Article 🗓️ Apr 15

🐭 Single psilocybin dose helps obese mice lose weight

  • Obese mice given one dose of psilocybin lost significantly more weight over four weeks when switched to low-fat food

  • The effect worked by reducing food intake rather than increasing energy expenditure

  • Psilocybin had no effect on mice that stayed on high-fat diets, suggesting it enhances rather than directly causes weight loss

💡 Psilocybin may help facilitate weight loss when combined with dietary changes.
🥉 Top 5% journal 🔗 Translational psychiatry Journal Article 🗓️ Apr 14

⚠️ Nearly half of psychedelic users report extended difficulties

  • Global survey of 6,476 psychedelic users found 48.3% experienced difficulties lasting 24+ hours, with 9.9% lasting over a year

  • Most common problems were existential struggle (36.6%), depression (34%), and derealization (29.4%)

  • Clinically disruptive difficulties lasting at least a month affected 8% of users and were linked to younger age, lower income, and pre-existing mental health conditions

💡 Extended adverse effects from psychedelics are more common than previously recognized.
🔗 Research square Preprint 🗓️ Apr 17

🧬 Brain support cells drive psilocybin's antidepressant effects

  • In chronically stressed mice, psilocybin reversed depression-like behaviors and prevented loss of astrocytes (brain support cells) in the prefrontal cortex

  • Lab studies showed psilocin (psilocybin's active form) directly enhanced astrocyte function, boosting their release of energy molecules and neurotransmitters

  • Depleting astrocytes in a specific brain region reduced psilocybin's antidepressant effects

💡 Astrocytes may be key players in how psilocybin treats depression.

🐟 Ayahuasca reverses chronic stress damage in zebrafish

  • Zebrafish exposed to 14 days of unpredictable stress showed impaired social behavior, increased anxiety, and elevated stress hormone cortisol

  • One hour of ayahuasca exposure completely reversed these stress-induced changes and restored normal brain-derived neurotrophic factor (BDNF) levels

  • The effects persisted beyond the acute exposure period

💡 A single ayahuasca exposure may reverse multiple biological markers of chronic stress.
Top 20% journal 🔗 Psychopharmacology Journal Article 🗓️ Apr 13

🎯 Psilocybin helps depression but not personality disorder symptoms

  • Nine adults with both borderline personality disorder and major depression received a single psilocybin dose

  • Depression scores dropped significantly from 28.56 to 17.22 over four weeks (Cohen's d=1.41, a large effect)

  • Borderline personality disorder symptoms showed no significant improvement

💡 Psilocybin may selectively target depression even in complex psychiatric presentations.
🔗 Clinical neuropharmacology Journal Article 🗓️ Apr 13

Implications

These studies reveal psychedelics work through multiple distinct biological pathways, with therapeutic effects potentially separable from psychoactive experiences. However, the high rates of extended difficulties and trial blinding failures highlight significant challenges for clinical development and patient safety.

Studies in this issue

Primary sources used for this newsletter.

  1. Separating the Hallucinogenic and Brain-Change Effects of Psilocybin
    main storybioRxiv : the preprint server for biology2026-04-17PMID 41993281
  2. Support cells in thinking areas help psilocybin produce fast antidepressant-like effects in stressed mice
    key findingProgress in neuro-psychopharmacology & biological psychiatry2026-04-13PMID 41974301
  3. Single Ayahuasca dose may reverse long-term stress effects on social behavior, anxiety, stress hormone, and brain growth factor in zebrafish
    key findingPsychopharmacology2026-04-13PMID 41974985
  4. Psilocybin’s effects on weight loss from diet in obese mice after one dose
    key findingTranslational psychiatry2026-04-14PMID 41980923
  5. How Well People Stay Unaware of Treatment in Psychedelic Drug Trials: A Review
    key findingJAMA psychiatry2026-04-15PMID 41984443
  6. How common and linked are ongoing challenges after psychedelic experiences worldwide
    key findingResearch square2026-04-17PMID 41994126
  7. Single-Dose Psilocybin for Borderline Personality Disorder with Major Depression: An Open-Label Study
    key findingClinical neuropharmacology2026-04-13PMID 41973961

Continue reading

All Psychedelic Science issues